Wharton's Jelly Explained: What It Is, What the Research Shows, and What It Isn't

Wharton's Jelly comes up often in conversations about regenerative medicine for joints. This article explains what it is, how it is sourced, what researchers have found so far, and where the limits are.

What Is Wharton's Jelly?

Wharton's Jelly is the soft, gelatinous connective tissue inside the umbilical cord. It surrounds and cushions the cord's blood vessels. It contains a matrix of hyaluronic acid and collagen, along with mesenchymal stromal cells (MSCs, often called mesenchymal stem cells) and a range of signaling molecules, including growth factors.

How It Is Sourced

Umbilical cord tissue is collected after healthy, full-term births, with informed consent from the donor. The collection occurs after birth and does not involve embryonic tissue. Reputable suppliers screen donors and process tissue in accredited facilities. Regenerative Revival sources biological materials from AATB-accredited tissue banks.

Why Researchers Are Interested

Laboratory studies show that Wharton's Jelly-derived MSCs can:

These are laboratory findings. They don't prove that injecting such cells into a human joint will rebuild cartilage, and the main proposed mechanism in joints is thought to be signaling, which may modulate inflammation, rather than the injected cells simply replacing damaged tissue.

What Clinical Research Shows

Studies of MSC-based injections for knee osteoarthritis have reported improvements in pain and function in some patients, but they vary widely in design, cell source, dose, and quality. Many are small, and published reviews consistently call for larger, well-controlled trials. Evidence specific to Wharton's Jelly is more limited still.

In plain terms: it is a promising area of research, not an established standard of care.

Regulation: What "Not FDA-Approved" Means

The FDA regulates cell- and tissue-based products. As of this writing, it has not approved any Wharton's Jelly-derived product for treating joint pain, arthritis, or other musculoskeletal conditions. Their use for those purposes is considered investigational. This does not mean they are automatically unsafe, but it does mean you should receive full informed consent, and that claims of guaranteed or "proven" outcomes should be treated with caution. Read the FDA's consumer guidance and the ISSCR patient resources for independent information.

Risks to Discuss

Any injection carries risks, including pain, swelling, bleeding, and infection at the injection site. Because these are biologic products, you should also ask about donor screening, sterility testing, and what is known about immune reactions. Your clinician should go over your specific risk profile.

Is It Right for You?

Candidacy depends on factors such as which joint is affected, the severity of damage on imaging, your health history, and your prior treatments. Some people are not candidates, and a good clinician will tell you so.

Learn More

Read our overview of Wharton's Jelly therapy, see how exosomes relate, or take the 2-minute consult quiz. Questions? Contact us.